First Drugmaker Sues Missouri Over its 340B Contract Pharmacy Access Law

AbbVie asked a federal district court to declare unconstitutional Missouri's 340B contract pharmacy access law.
Pharmaceutical giant AbbVie yesterday became the first drugmaker to file suit against Missouri’s new law prohibiting 340B contract pharmacy restrictions [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Merck, Jazz Pharmaceuticals Exempt States from 340B Contract Pharmacy Restrictions — Including First for Missouri

Merck became the first drugmaker to announce it would loosen its 340B contract pharmacy restrictions in Missouri in response to a new state law.
Merck will loosen its 340B contract pharmacy restrictions in Minnesota and Missouri, becoming the first drugmaker to officially update its [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

News Alert

Massachusetts 340B Measures Addressing PBM Discrimination and Medicaid Drug Coverage Fall Short in Senate, Sponsor Plans to Refile Bill Next Session

A contract pharmacy access bill could still pass in Massachusetts despite the end of the formal legislative session.
The Massachusetts Senate on Thursday failed to adopt legislation that would have prohibited pharmacy benefit managers (PBMs) from imposing discriminatory [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

State Contract Pharmacy Lawsuit Weekly Roundup: Updates in Mississippi, Maryland

Federal district courts in Maryland and Mississippi saw various legal actions related to state 340B contract pharmacy access laws in the past week.
Editor’s Note: With 340B-related litigation heating up in several states following the enactment of new contract pharmacy access laws this summer, [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

SK Life Science Posts Refund Notice; Dr. Reddy’s and Pfizer Issue NDC Changes

Amgen announced a change to the national drug code for its osteoporosis drug, Prolia.
SK Life Science issued a refund notice for an epilepsy drug following a 340B price ceiling recalculation. Multiple drug manufacturers [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

CMS Proposes Rule to Exclude 340B Claims from Inflation Rebates; Reflects ‘Stronger Understanding’ of 340B than IRA Negotiation Guidance, Says Attorney

CMS recently proposed a rule to fulfill its statutory obligation to exclude 340B claims from Medicare inflationary rebates.
The Centers for Medicare & Medicaid Services (CMS) has outlined how it plans to identify 340B claims to remove when [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Study Finds Oncology Markups at 340B Pediatric Hospitals; AHA Slams Study and Funder 

New research looked at the prices 340B-enrolled pediatric hospitals charged for pediatric oncology drugs.
The rates 340B pediatric hospitals negotiate with payers for new pediatric oncology drugs often exceed a medication’s average sale price, [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Sumitomo Loosens 340B Contract Pharmacy Restrictions in Five More States

Sumitomo Pharma America loosened or ended its 340B contract pharmacy restrictions in an additional five states.
Drugmaker Sumitomo Pharma America (SMPA) is partially or fully exempting providers in five additional states from its 340B contract pharmacy [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Pharma-Linked Conservative Nonprofit Launches Ad Campaign to ‘Stop the Feeding Frenzy’ in 340B

The Council for Citizens Against Government Waste has launched a new ad campaign that criticizes the 340B program.
An anti-government waste group with ties to the drug industry is urging lawmakers to “stop the feeding frenzy” in the [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Drug Industry Takes Issue with IRA’s Drug Negotiation Guidance

PhRMA recently urged CMS to establish a neutral clearinghouse and require accurate use of 340B claim modifiers to address nonduplication in its final guidance for Medicare drug price negotiations under the IRA.
Editor’s Note: In Tuesday’s issue, we looked at comments from 340B provider stakeholders, today we look more closely at the [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live